Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : APN431
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Apeiron Biologics
Deal Size : Undisclosed
Deal Type : Partnership
Expansion of APEIRON Biologics and Domainex Partnership will Advance Cancer Drug Discovery
Details : Domainex will provide its expertise in medicinal and computational chemistry, screening, structural biology and ADME/PK to advance APEIRON’s promising Cbl-b targeting compound series APN431 towards pre-clinical development.
Brand Name : APN431
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 09, 2020
Lead Product(s) : APN431
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : Apeiron Biologics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Undisclosed
Therapeutic Area : Hematology
Study Phase : Discovery
Sponsor : LUNAC Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Domainex inks partnership with LUNAC Therapeutics to discover novel anticoagulant therapies
Details : The partnership aims at discovering a drug that inhibits the protease target, activated Factor XII.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
February 25, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Hematology
Highest Development Status : Discovery
Sponsor : LUNAC Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?